Oculus Spinout Ruthigen Focusing on Infection Drug
By Catherine Shaffer
Monday, January 14, 2013
Oculus Innovative Sciences Inc., of Petaluma, Calif., spun out a new biotechnology business to develop a drug candidate for infection in trauma and surgical procedures. The company, named Ruthigen Inc., will be headed by Hoji Alimi, the current CEO of Oculus.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.